SCHEMBL19902628

SCHEMBL19902628

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cc2cccnc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.48
CNR2 P34972 1/20 0.44
NUDT1 P36639 2/20 0.42
ROCK2 O75116 2/20 0.42
ACKR3 P25106 1/20 0.41
ROCK1 Q13464 2/20 0.41
MAPK8 P45983 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40
HRH4 Q9H3N8 2/20 0.39
SMYD3 Q9H7B4 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
DAO P14920 1/20 0.38
HDAC1 Q13547 1/20 0.38
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
DRD3 P35462 1/20 0.37
LIPG Q9Y5X9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452822 0.89 ROCK2 (0.54) RIPK1CNR2NUDT1ROCK2ACKR3
SCHEMBL19902458 0.87 SCN4A (0.48) ROCK2MAPK8MEN1NPC1KMT2A
SCHEMBL19902699 0.84 PLA2G7 (0.53) ROCK2MAPK8MEN1NPC1KMT2A
SCHEMBL19902413 0.83 SMYD3 (0.61) RIPK1ROCK2MAPK8HRH4SMYD3
SCHEMBL19902488 0.83 SMYD3 (0.46) RIPK1ROCK2MAPK8HRH4SMYD3
SCHEMBL19902711 0.83 PYGL (0.48) NUDT1ROCK2ROCK1MAPK8SMYD3
SCHEMBL19902625 0.81 MLLT1 (0.49) ROCK2ROCK1MAPK8MEN1NPC1
SCHEMBL19902581 0.81 SMYD3 (0.46) ROCK2HRH4SMYD3HDAC1PLA2G7
SCHEMBL19902463 0.81 SLC2A1 (0.46) ROCK2MAPK8HRH4SMYD3PLA2G7
SCHEMBL19902356 0.79 CHRNA7 (0.45) ROCK2ROCK1MAPK8NPC1SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 RIPK1 685/4885CNR2 2319/4885NUDT1 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.